Trevi Therapeutics
Trevi Therapeutics Inc is an American clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER) for neurologically mediated conditions. The company advances Haduvio, an investigational dual kappa opioid receptor agonist and mu opioid receptor antagonist, targeting chronic cough in idiopathic pulmonary fibrosis and chronic pruritus in prurigo nodularis. Main revenue drivers currently comprise investment capital financing, research grants, and potential milestone licensing payments as clinical trials progress. Trevi Therapeutics targets pulmonologists, dermatologists, clinical research hospitals, and chronic disease patients across North America and Europe. The company holds an innovative position in central nervous system-mediated respiratory and dermatological drug development. Headquartered in New Haven, Connecticut, Trevi Therapeutics Inc is listed on the Nasdaq Stock Market.
3 of the funds FundTelligence covers report a position in Trevi Therapeutics.
- Legal name
- TREVI THERAPEUTICS
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
Funds holding Trevi Therapeutics
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.13 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.01 % (full portfolio disclosed, September 2026)